Skip to main content
Supplement Research and Comparison WebsiteBest Price Guarantee
Supplement Research and Comparison Website

Bifidobacteriumlongum subsp. infantis CECT7210 (B. infantis IM-1®) Displays In Vitro Activity against Some Intestinal Pathogens

  • 2020-10-24
  • Nutrients 12(11)
    • L. Ruiz
    • A. Flórez
    • B. Sánchez
    • J. A. Moreno-Muñoz
    • M. Rodriguez-Palmero
    • J. Jiménez
    • C. G. D. L. R. Gavilán
    • M. Gueimonde
    • P. Ruas-Madiedo
    • A. Margolles

Abstract

Certain non-digestible oligosaccharides (NDO) are specifically fermented by bifidobacteria along the human gastrointestinal tract, selectively favoring their growth and the production of health-promoting metabolites. In the present study, the ability of the probiotic strain Bifidobacterium longum subsp. infantis CECT7210 (herein referred to as B. infantis IM-1®) to utilize a large range of oligosaccharides, or a mixture of oligosaccharides, was investigated. The strain was able to utilize all prebiotics screened. However, galactooligosaccharides (GOS), and GOS-containing mixtures, effectively increased its growth to a higher extent than the other prebiotics. The best synbiotic combination was used to examine the antimicrobial activity against Escherichia coli, Cronobacter sakazakii, Listeria monocytogenes and Clostridium difficile in co-culture experiments. C. difficile was inhibited by the synbiotic, but it failed to inhibit E. coli. Moreover, Cr. sakazakii growth decreased during co-culture with B. infantis IM-1®. Furthermore, adhesion experiments using the intestinal cell line HT29 showed that the strain IM-1® was able to displace some pathogens from the enterocyte layer, especially Cr. sakazakii and Salmonella enterica, and prevented the adhesion of Cr. sakazakii and Shigella sonnei. In conclusion, a new synbiotic (probiotic strain B. infantis IM-1® and GOS) appears to be a potential effective supplement for maintaining infant health. However, further studies are needed to go more deeply into the mechanisms that allow _B._infantis IM-1® to compete with enteropathogens.

Keywords: Bifidobacterium longum; enteropathogens; prebiotics; probiotics; synbiotic.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium infantisPrevented Shigella sonnei AdhesionBeneficial
Moderate
Bifidobacterium infantisReduced Clostridium difficile InfectionBeneficial
Moderate
Bifidobacterium infantisReduced Colonization of Cronobacter sakazakii in EnterocytesBeneficial
Moderate
Bifidobacterium infantisReduced Cronobacter sakazakii AdhesionBeneficial
Moderate
Bifidobacterium infantisReduced Enterocyte Layer Colonization by Salmonella entericaBeneficial
Moderate
Bifidobacterium infantisReduced Growth of Cronobacter sakazakiiBeneficial
Moderate
Bifidobacterium infantis BI02Prevented Shigella sonnei AdhesionBeneficial
Moderate
Bifidobacterium infantis BI02Reduced Clostridium difficile InfectionBeneficial
Moderate
Bifidobacterium infantis BI02Reduced Colonization of Cronobacter sakazakii in EnterocytesBeneficial
Moderate
Bifidobacterium infantis BI02Reduced Enterocyte Pathogen LoadBeneficial
Moderate
Bifidobacterium infantis BI02Reduced Growth of Cronobacter sakazakiiBeneficial
Moderate
Bifidobacterium infantis M-63Reduced Clostridium difficile CountBeneficial
Large
Bifidobacterium infantis M-63Reduced Growth of Cronobacter sakazakiiBeneficial
Moderate
Bifidobacterium infantis MAK22B04IReduced Clostridium difficile InfectionBeneficial
Moderate
Bifidobacterium infantis MAK22B04IReduced Growth of Cronobacter sakazakiiBeneficial
Moderate
Bifidobacterium infantis SD-6720Reduced Clostridium difficile InfectionBeneficial
Moderate
Bifidobacterium infantis SD-6720Reduced Enteropathogen AdhesionBeneficial
Moderate
Bifidobacterium infantis SD-6720Reduced Enteropathogen ColonizationBeneficial
Moderate
Bifidobacterium infantis SD-6720Reduced Growth of Cronobacter sakazakiiBeneficial
Moderate
Bifidobacterium infantis VPro 53Increased Bifidobacteria GrowthBeneficial
Large
Bifidobacterium infantis VPro 53Reduced Clostridium difficile InfectionBeneficial
Moderate
Bifidobacterium infantis VPro 53Reduced Enteropathogen Presence in Enterocyte LayerBeneficial
Large
Bifidobacterium infantis VPro 53Reduced Growth of Cronobacter sakazakiiBeneficial
Moderate
Bifidobacterium longum subsp. infantisReduced Clostridium difficile InfectionBeneficial
Moderate
Bifidobacterium longum subsp. infantisReduced Growth of Cronobacter sakazakiiBeneficial
Moderate
Back to top